Peroxitech
PA - PhiladelphiaBiotechnology
Focus: Peroxitech is a Philadelphia-based biotechnology company focused on developing peptide treatments for acute lung injury, specifically targeting the critical care respiratory market.
Profile data last refreshed 3h ago · AI intelligence enriched 1w ago
Open Jobs
0
About Peroxitech
AI assessmentNot HiringNo open roles listed right now. Follow Peroxitech to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. Thes
ARDS (Acute Respiratory Distress Syndrome)Clinical Trials (1)
NCT07125079Lung Injury is One of the Primary Causes of Morbidity and Mortality in Critically Ill Patients. These Patients Will be Monitored for: 1) Immune Cell Activation 2) Blood-based Biomarkers. In Vitro Models Derived From These Samples Will be Treated With Novel Agent PIP-2 to Evaluate Its Efficacy.
Help build intelligence for Peroxitech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.